B. Riley analyst Kalpit Patel lowered the firm’s price target on Allogene Therapeutics to $15 from $18 and keeps a Buy rating on the shares post the Q4 results. The analyst consider the shares to be undervalued on the prospects for ALLO-501A.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALLO:
- Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
- Allogene Therapeutics reports Q4 EPS (66c), consensus (54c)
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
- Allogene Therapeutics presents preclinical Dagger platform technology data
